Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
This study has been completed.
Sponsor:
Pfizer
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00334750
First received: June 5, 2006
Last updated: September 8, 2010
Last verified: September 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
| Condition | Intervention |
|---|---|
|
Glaucoma, Open-Angle Ocular Hypertension |
Other: There is no intervention in this study. |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada |
Resource links provided by NLM:
Further study details as provided by Pfizer:
Primary Outcome Measures:
- To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice. [ Time Frame: duration of study ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation. [ Time Frame: duration of study ] [ Designated as safety issue: No ]
| Enrollment: | 410 |
| Study Start Date: | November 2007 |
| Study Completion Date: | April 2009 |
| Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
There is no intervention in this study
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
|
Other: There is no intervention in this study.
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Canadian population
Criteria
Inclusion Criteria:
- Subjects diagnosed at study visit or within 3 months of visit with OH
- OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)
Exclusion Criteria:
- No prior treatment for OH or OAG
- No prior ocular surgery or history of ocular trauma
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00334750
Locations
| Canada, Alberta | |
| Pfizer Investigational Site | |
| Calgary, Alberta, Canada, T3E 7M8 | |
| Pfizer Investigational Site | |
| Edmonton, Alberta, Canada, T5H 0X5 | |
| Pfizer Investigational Site | |
| Edmonton, Alberta, Canada, T5H 3V9 | |
| Canada, British Columbia | |
| Pfizer Investigational Site | |
| Nanaimo, British Columbia, Canada, V9R 5B6 | |
| Pfizer Investigational Site | |
| Vancouver, British Columbia, Canada, V6K 1V7 | |
| Pfizer Investigational Site | |
| Williams Lake, British Columbia, Canada, V2G 1H1 | |
| Canada, Manitoba | |
| Pfizer Investigational Site | |
| Winnipeg, Manitoba, Canada, R3C 0N2 | |
| Canada, Nova Scotia | |
| Pfizer Investigational Site | |
| Sydney, Nova Scotia, Canada, B1P 1P2 | |
| Canada, Ontario | |
| Pfizer Investigational Site | |
| Brampton, Ontario, Canada, L6V 1B4 | |
| Pfizer Investigational Site | |
| Hamilton, Ontario, Canada, L8M 1L6 | |
| Pfizer Investigational Site | |
| London, Ontario, Canada, N6A 4V2 | |
| Pfizer Investigational Site | |
| Mississauga, Ontario, Canada, L5L 1W8 | |
| Pfizer Investigational Site | |
| Oakville, Ontario, Canada, L6H 3P1 | |
| Pfizer Investigational Site | |
| Oakville, Ontario, Canada, L6L 5G8 | |
| Pfizer Investigational Site | |
| Toronto, Ontario, Canada, M4N 3M5 | |
| Pfizer Investigational Site | |
| Toronto, Ontario, Canada, M5M 1B2 | |
| Pfizer Investigational Site | |
| Toronto, Ontario, Canada, M5T 2S8 | |
| Canada, Quebec | |
| Pfizer Investigational Site | |
| Montreal, Quebec, Canada, H1T 2M4 | |
| Pfizer Investigational Site | |
| Montreal, Quebec, Canada, H1V 1G5 | |
| Pfizer Investigational Site | |
| Sherbrooke, Quebec, Canada, J1K 1EB | |
| Canada, Saskatchewan | |
| Pfizer Investigational Site | |
| Saskatoon, Saskatchewan, Canada, S7K 3H3 | |
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
No publications provided
| Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer Inc |
| ClinicalTrials.gov Identifier: | NCT00334750 History of Changes |
| Other Study ID Numbers: | A6111125 |
| Study First Received: | June 5, 2006 |
| Last Updated: | September 8, 2010 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Pfizer:
|
Glaucoma, Open-Angle Ocular Hypertension Risk factors Canadian |
Additional relevant MeSH terms:
|
Glaucoma Glaucoma, Open-Angle Hypertension Ocular Hypertension |
Eye Diseases Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on October 16, 2012
